| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00000421-200110000-00016 |
| P698 | PubMed publication ID | 11586103 |
| P50 | author | Philip T Reiss | Q51363911 |
| P2093 | author name string | T Moore | |
| M Steinhoff | |||
| L Chai | |||
| R Mass | |||
| L Goldstein | |||
| T C King | |||
| U Tantravahi | |||
| H Safran | |||
| R Rathore | |||
| S Mangray | |||
| P Akerman | |||
| D Iannitti | |||
| D Quirk | |||
| K Berzein | |||
| T Pasquariello | |||
| P433 | issue | 5 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| overexpression | Q61643320 | ||
| P304 | page(s) | 496-499 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | American Journal of Clinical Oncology | Q2886177 |
| P1476 | title | Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. | |
| P478 | volume | 24 |
| Q33398693 | A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer |
| Q35886631 | Adjuvant and neoadjuvant treatment in pancreatic cancer |
| Q34127857 | Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. |
| Q37390655 | Anti-ERBB2 sh-RNA suppress both cell growth and tumor growth in ERBB2-overexpressing upper gastrointestinal adenocarcinomas |
| Q36245510 | Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer |
| Q91622958 | Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma |
| Q37242685 | Biologic therapies for advanced pancreatic cancer |
| Q39202440 | CAR T-cell therapy for pancreatic cancer. |
| Q37799830 | Challenges of drug resistance in the management of pancreatic cancer |
| Q88574706 | Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice |
| Q30410012 | Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer |
| Q58610296 | Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine |
| Q40672605 | Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line |
| Q37777082 | Current Diagnosis and Future Impact of Micrometastases for Therapeutic Strategies in Adenocarcinoma of the Esophagus, Gastric Cardia, and Upper Gastric Third |
| Q39028976 | Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy |
| Q81425258 | Current status of monoclonal antibodies as therapeutic agents for solid cancer |
| Q33788222 | Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater |
| Q35148592 | Drug development in pancreatic cancer: finally, biology begets therapy |
| Q39257360 | EGFR and HER2 inhibition in pancreatic cancer |
| Q39821603 | ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas |
| Q35350578 | Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET |
| Q93155695 | Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies |
| Q39158427 | Emerging antibodies for the treatment of pancreatic cancer. |
| Q89622506 | ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1 |
| Q35987242 | Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma |
| Q59549057 | Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer |
| Q79401515 | Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus |
| Q46362755 | Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation |
| Q64252172 | Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer |
| Q34446744 | Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing |
| Q36734936 | HER family inhibitors in pancreatic cancer: current status and future directions |
| Q47802235 | HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis |
| Q45174616 | Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu |
| Q35836035 | In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption |
| Q39095666 | In vitro evaluation of HPMA-copolymers targeted to HER2 expressing pancreatic tumor cells for image guided drug delivery |
| Q37181675 | Induction of apoptosis and the regulation of ErbB signaling by laminarin in HT-29 human colon cancer cells |
| Q38073827 | Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers |
| Q36180532 | Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma |
| Q35857856 | Monoclonal antibodies as effective therapeutic agents for solid tumors |
| Q35832274 | Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer |
| Q35651453 | New targeted therapies in pancreatic cancer |
| Q35604577 | Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future |
| Q40540903 | Overexpression of synuclein-gamma in pancreatic adenocarcinoma |
| Q36475141 | Pancreatic adenocarcinoma -- genetic portrait from chromosomes to microarrays |
| Q36600002 | Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis |
| Q38608986 | Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells |
| Q33638654 | Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status |
| Q35599597 | Review article: chemotherapy for pancreatic cancer. |
| Q54610409 | Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. |
| Q38019898 | Targeted therapy for gastric cancer--current status |
| Q35741633 | Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer |
| Q37941807 | Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma |
| Q35108011 | The Medical Management of Pancreatic Cancer: A Review |
| Q34494019 | The molecular targets for the diagnosis and treatment of pancreatic cancer |
| Q36773130 | The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer |
| Q55483367 | Therapeutic antibodies for the treatment of pancreatic cancer. |
| Q35811043 | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells |
Search more.